Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Net Cash Flow (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Net Cash Flow for 11 consecutive years, with $7.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow rose 494.4% to $7.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.9 million, a 218.21% increase, with the full-year FY2024 number at $4.1 million, down 56.71% from a year prior.
  • Net Cash Flow was $7.1 million for Q3 2025 at Marker Therapeutics, up from -$1.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $43.2 million in Q1 2021 to a low of -$14.7 million in Q1 2022.
  • A 5-year average of $194175.8 and a median of -$3.0 million in 2022 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: skyrocketed 1282.69% in 2021, then tumbled 139.45% in 2024.
  • Marker Therapeutics' Net Cash Flow stood at -$5.2 million in 2021, then crashed by 83.4% to -$9.6 million in 2022, then soared by 75.92% to -$2.3 million in 2023, then skyrocketed by 543.26% to $10.2 million in 2024, then plummeted by 30.07% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Net Cash Flow are $7.1 million (Q3 2025), -$1.9 million (Q2 2025), and -$5.5 million (Q1 2025).